<DOC>
	<DOCNO>NCT00749385</DOCNO>
	<brief_summary>A pharmacokinetic study evaluate naproxen esomeprazole blood level 4 treatment , contain one component .</brief_summary>
	<brief_title>A Pharmacokinetic ( PK ) Study Evaluating Naproxen Esomeprazole Plasma Levels</brief_title>
	<detailed_description>This study conduct assess relative bioavailability naproxen esomeprazole single dose PN 400 ( delayed-release naproxen 500mg / immediate-release esomeprazole 20mg ) , enteric-coated naproxen 500mg co-administered enteric-coated esomeprazole 20mg , enteric-coated naproxen 500mg administer alone , enteric-coated esomeprazole 20mg administer alone .</detailed_description>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Healthy male nonpregnant , nonlactating female either nonchildbearing potential use acceptable method birth control . Standard exclusion criterion study nature significant medical condition might affect interpretation PK data compromise safety subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>